Effects of Immunosuppression on HCV Recurrence After Living Donor Liver Transplantation - Comparative Study Between Tacrolimus + MMF and Tacrolimus + Steroid
NCT ID: NCT00469131
Last Updated: 2011-09-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
79 participants
INTERVENTIONAL
2003-09-30
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Reduction of Tacrolimus Dose in Association With Mycophenolate Mofetil After Liver Transplantation
NCT00151632
Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen
NCT00286871
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
NCT00105235
Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation
NCT00710801
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
NCT00163657
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 Drug:
tacrolimus + steroid
tacrolimus + steroid
2 Drug:
tacrolimus + mycophenolate mofetil
tacrolimus + mycophenolate mofetil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tacrolimus + steroid
tacrolimus + mycophenolate mofetil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Renal dysfunction (serum creatinine \>2.0 mg/dL)
* WBC \< 1,000/mm3
* Hemoglobin \< 8 g/dL
* Platelet \<30,000 /mm3
18 Years
69 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kyoto University
OTHER
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyoto University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shinji Uemoto, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Kyoto University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyoto University Hospital
Kyoto, Kyoto, Japan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transpl. 2013 Aug;19(8):896-906. doi: 10.1002/lt.23679.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHA-LD-03-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.